Beta Bionics, Inc.
BBNX
$22.26
$1.778.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | 54.45% | 36.39% | 144.79% | 440.09% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 54.45% | 36.39% | 144.79% | 440.09% | |
| Cost of Revenue | 54.19% | 51.22% | 166.15% | 317.08% | |
| Gross Profit | 54.66% | 24.58% | 130.92% | 627.67% | |
| SG&A Expenses | 73.86% | 79.18% | 72.95% | 139.72% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 60.68% | 62.07% | 100.26% | 133.11% | |
| Operating Income | -68.64% | -97.21% | -55.81% | -24.99% | |
| Income Before Tax | -16.64% | -130.19% | 3.93% | -12.17% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -16.64% | -130.19% | 3.93% | -12.17% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -16.64% | -130.19% | 3.93% | -12.17% | |
| EBIT | -68.64% | -97.21% | -55.81% | -24.99% | |
| EBITDA | -70.00% | -100.08% | -58.58% | -25.97% | |
| EPS Basic | 83.59% | 54.87% | 13.12% | 9.35% | |
| Normalized Basic EPS | 83.59% | 54.87% | 13.12% | 9.35% | |
| EPS Diluted | 83.59% | 54.87% | 13.12% | 9.35% | |
| Normalized Diluted EPS | 83.59% | 54.87% | 13.12% | 9.35% | |
| Average Basic Shares Outstanding | 610.65% | 410.05% | 10.59% | 23.74% | |
| Average Diluted Shares Outstanding | 610.65% | 410.05% | 10.59% | 23.74% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |